A group of renowned and highly specialized scientists form the core of Profil. Divided into several teams, they specialize in each of our focus areas of diabetes- and obesity-related medication and technology. Our scientists are dedicated to improving the diagnosis, treatment and quality of life for people suffering from diabetes and obesity.
Furthermore, our R&D and Science and Innovation departments ensure that our expertise on clinical research and healthcare innovation develop continuously, thereby contributing to the most optimal outcome for our clients.
Read about our leading scientists and their teams.
Director Clinical Pharmacology
Grit is a clinical pharmacologist and has been with Profil for several years and among other responsibilities she is running the specialization program in clinical pharmacology for medical doctors.
Sabine has worked in diabetes for more than 20 years with a background in both academia and 9 years pharmaceutical industry. She has been Principal Investigator for clamp trials and the artifical pancreas trials (AP@Home). Currently she is also building a network with diabetologists and GP practices.
Director Technical Development
Carsten is a physicist in the field of nano-structured surfaces on condensed matter and has long-term experience in hardware and software development of medical devices. At Profil he is the Director of Technical Development and manager of the AP@home EU project.
Scientific Study Advisor
Susanne has a special focus on biosimilars and is very experienced in conducting trials in this field. Her efforts drive forward the achievements of Profil's project development team.
Director Medical Science
Thomas has over 30 years of experience in clinical research with special expertise in the field of diabetes mellitus and its vascular complications. He has authored or co-authored in excess of 250 original articles in peer reviewed international journals.
Lead ScientistTim has over 25 years of experience in clinical research and care in diabetes and obesity. He has published >120 scientific papers and reviews focussing on the pharmacology of insulin and anti-diabetic drugs. He is on the Editorial Board for Diabetes, Obesity and Metabolism.
Scientific Study Advisor
As Ulrike has many years of experience in the clinical setting at Profil and now uses this expertise in the project development team to drive project excellence.
Chief Executive Officer
Christoph has >20 years of diabetes research experience in the development of drugs, and devices. He has consulted in the clinical development plans of several new therapeutic entities. His particular expertise lies in the field of incretin hormones.
Scientific Study AdvisorOliver has several years of clinical experience and combines this with his scientific accumen to optimize the study design for novel antidiabetic drug developments.
Scientific Study AdvisorDaniela has an academic background with special focus on molecular biology. During her PhD thesis at the German Diabetes Center in Düsseldorf she identified novel adipocyte-secreted factors and investigated their impact on the development of insulin resistance.
Chief Executive Officer - Profil Mainz
Leona has profound expertise in the field of obesity, diabetes, and metabolism. She has a strong research background in academia and industry with particular know-how in basic science of molecular endocrinology and energy metabolism.
Director Science & InnovationFreimut is a biochemist with longstanding scientific activities in the fields of experimental hepatology and molecular medicine. His focus is the advancement of Profil's innovation project portfolio.
Director Project Development/ Medical TechnologyEric started his professional career in 2008 as Scientific Study Advisor at Profil. With an academic background in biomedical engineering and physiology, he has the capabilities to translate across and combine these two fields of science.